Home » KUS-121 shows therapeutic potential in models of atherosclerotic disease

To read the full story, subscribe or sign in.

Cardiovascular

KUS-121 shows therapeutic potential in models of atherosclerotic disease

Sep. 3, 2024

The valosin-containing protein (VCP) modulator KUS-121 from Kyoto University is in phase II development as an intravitreal treatment for nonarteritic central retinal artery occlusion, but its efficacy in atherosclerosis is unknown.

BioWorld Science Conferences European Society of Cardiology Cardiovascular

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 10, 2025
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology
BioWorld
About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...